In addition to the cost, the excessive overuse of laboratory testing causes patient discomfort and can lead to hospital-acquired anemia, which results in additional testing, prolonged hospitalizations, unnecessary transfusions, and increased mortality for patients with cardiopulmonary diseases.
As healthcare expenditures continue to increase, there is a growing substantial interest in promoting high-value care initiatives.
With the excessive amount of daily laboratory testing of hospitalized patients being a prevalent clinical issue, JAMA Internal Medicine published an evidence-based implementation blueprint to guide the appropriate amount of routine laboratory testing.
“Although laboratory expenditure often represents less than 5% of most hospital budgets, the impact is far-reaching given that laboratory tests influence nearly 60% to 70% of all medical decisions,” wrote the authors.
In addition to the cost, phlebotomy overuse causes patient discomfort and can lead to hospital-acquired anemia, which results in additional testing, prolonged hospitalizations, unnecessary transfusions, and increased mortality for patients with cardiopulmonary diseases.
In a previous study of 17,676 patients, researchers found that approximately 20% of hospitalized patients developed “moderate to severe hospital-acquired anemia.” A single-center observational study discovered a direct correlation between the volume of phlebotomy and the decrease in hemoglobin levels. However, implementing guidelines on how to prevent this is challenging because there are many contributing factors to laboratory test overuse, such as insufficient knowledge of laboratory costs, fear of litigation, and differing levels of healthcare professionals’ training.
Hospitals that have attempted a reduction of routine daily laboratory tests have focused on 3 strategies: education, audit and feedback on provider ordering practices, and electronic health record (EHR)-enabled restrictive ordering. The most successful interventions were the ones that implemented a combination of these strategies.
Analyzing past intervention strategies, the authors of this study created an algorithm as a guide to reducing the excessive use of routine daily laboratory testing. However, the algorithm must be paired with the willingness to change within an institution for it to be effective, the authors wrote. Utilizing the 3 commonly used strategies, the authors came up with the following:
“This intervention can catalyze a commitment to improve high-value practices across the whole enterprise, which ultimately will result in improved safety, satisfaction, and cost-effectiveness for all stakeholders,” concluded the authors.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More